Dr. Fei Xu 徐菲
Chief Physician, Lecturer
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for breast cancer, including chemotherapy and targeted therapy. Research on new anti-cancer drugs.
Dr. Xu holds a PhD in Oncology and is a Chief Physician and Master’s Supervisor. Graduating from Sun Yat-sen University of Medical Sciences in 2000, Dr. Xu has worked in medical oncology at Sun Yat-sen University Cancer Center since then, with clinical training at Prince of Wales Hospital in Hong Kong (2012–2013). Focus includes breast cancer treatment and anti-cancer drug research.
Professional roles
- Member, Breast Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Breast Tumor Integrated Rehabilitation Committee, China Anti-Cancer Association (CACA)
- Standing Committee Member, Chemotherapy Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member and Secretary-General, Breast Cancer Diagnosis and Treatment Quality Control Expert Committee, Guangdong Cancer Center
Name order: in Chinese the family name comes first (Xu Fei). Papers usually list the name as Fei Xu or Xu F.
Selected publications
105 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gland Surg, 2026 (first author): Development and validation of a SEER-based prognostic nomogram for overall survival in elderly Asian American women with breast cancer. PubMed 42725317
- NPJ Breast Cancer, 2023 (senior author): The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. PubMed 37085500
- Oncol Res Treat, 2022 (senior author): BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. PubMed 34818649
- Front Oncol, 2021 (senior author): Miller-Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy. PubMed 34631568
- Oncologist, 2021 (first author): A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy. PubMed 33245164
- Dis Markers, 2021 (first author): The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. PubMed 33628341
- Oncologist, 2020 (first author): Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study. PubMed 32058619
- Cancers (Basel), 2020 (first author): Hypermethylation of SCAND3 and Myo1g Gene Are Potential Diagnostic Biomarkers for Hepatocellular Carcinoma. PubMed 32824823
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion